Compare OPTU & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPTU | QURE |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.5M | 663.4M |
| IPO Year | N/A | 2013 |
| Metric | OPTU | QURE |
|---|---|---|
| Price | $1.48 | $17.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $2.00 | ★ $39.33 |
| AVG Volume (30 Days) | 1.7M | ★ 4.3M |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.14 |
| Revenue Next Year | N/A | $395.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.38 | $7.76 |
| 52 Week High | $2.14 | $71.50 |
| Indicator | OPTU | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 40.08 | 47.05 |
| Support Level | N/A | $13.29 |
| Resistance Level | $1.97 | $26.84 |
| Average True Range (ATR) | 0.09 | 2.19 |
| MACD | 0.00 | -0.60 |
| Stochastic Oscillator | 36.63 | 53.27 |
Optimum Communications Inc acquired privately held US cable company Suddenlink in 2015 and Cablevision in 2016. Suddenlink's networks provide television, internet access, and phone services to roughly 4.5 million US homes and businesses located primarily in smaller markets, with major clusters in Texas, West Virginia, Idaho, Arizona, and Louisiana. Cablevision provides comparable services to about 5.5 million homes and businesses in the New York City metro area. Both regions now operate under the Optimum brand name. Altice Europe spun off Altice USA, which includes both the Suddenlink and Cablevision operations, to shareholders in 2018. Altice USA also owns News 12 Networks, which broadcasts local news in New York.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.